CRISPR/Cas9 Archives -

Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance

https://pharmaphorum.com/news/vertex-eyes-controllable-genetic-drugs-with-1-3bn-obsidian-alliance/

ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disorders

https://pharmaphorum.com/news/ash-crispr-vertex-ctx001-hits-the-mark-in-red-cell-disorders/

Biogen teams up with gene-editing startup Scribe on ALS programme

https://pharmaphorum.com/news/biogen-teams-up-with-gene-editing-startup-scribe-on-als-programme/

CRISPR pioneers Doudna and Charpentier claim Nobel chemistry prize

https://pharmaphorum.com/news/crispr-pioneers-doudna-and-charpentier-claim-nobel-chemistry-prize/

First patient dosed in trial of Allergan/Editas’ CRISPR blindness drug

https://pharmaphorum.com/news/first-patient-dosed-in-trial-of-allergan-editas-crispr-blindness-drug/

CRISPR trials yield encouraging data in blood disorders

https://pharmaphorum.com/news/crispr-trials-yield-encouraging-data-in-blood-disorders/

Broad, MilliporeSigma issue call to make access to CRISPR freer

https://pharmaphorum.com/news/broad-milliporesigma-issue-call-to-make-access-to-crispr-freer/

Vertex licenses back CRISPR compounds from German Merck

https://pharmaphorum.com/news/vertex-licenses-back-crispr-compounds-from-german-merck/

Dr. Dana Carroll to deliver keynote on challenges in Programmable Genome Editing.

https://pharmaphorum.com/partner-content/dr-dana-carroll-deliver-keynote-challenges-programmable-genome-editing/

Search